ABSTRACT
Objective: To investigate the prevalence of fibromyalgia [FM] among patients with Hashimoto's thyroiditis [HT] and association of thyroid antibodies with FM severity among affected individuals
Design: Cross-sectional
Setting: Two endocrinology outpatient clinics
Subjects: Euthyroid patients with HT were recruited
Intervention: Assessment for detection of fibromyalgia
Main outcome measure[s]: Prevalence of fibromyalgia and association with Hashimoto's thyroiditis. Diagnosis of FM was made using the 2010 American College of Rheumatology criteria. Serum concentrations of thyroid stimulating hormone [TSH] and anti-thyroid peroxidase [anti-TPO] antibodies were determined
Results: Average age of the patients was 38.5 years and 93.1% were female. Among the 102 patients, diagnosis of FM was made in five patients [prevalence rate, 95% CI: 4.9%, 0.7 - 9.1]. Age, sex, level of education, marital status, menopause status, duration of thyroid disease, TSH, and anti-TPO concentrations were comparable between patients with and without FM [p >0.05 in all tests]. Among patients with FM, the indices of FM severity [widespread pain index, and symptom severity] were not significantly correlated with wither TSH or anti-TPO concentrations
Conclusion: Despite previous reports suggesting an increased risk of FM in HT, among Iranian patients with HT, the prevalence of FM seems to be comparable with the prevalence reported in the female general population. A possible link between HT and FM needs further investigation in large population-based studies
ABSTRACT
Given the relationship of vitamin D deficiency with insulin resistance syn-drome as the component of polycystic ovary syndrome [PCOS], the main aim of this study was to compare serum level of 25- hydroxyvitamin D [25[OH]D] between PCOS patients and normal individuals. A cross sectional study was conducted to compare 25[OH]D level between117 normal and 125 untreated PCOS cases at our clinic in Arash Hospital, Tehran, Iran, during 2011-2012. The obtained levels of 25[OH]D were classified as follows: lower than 25 nmol/ml as severe deficiency, between 25-49.9 nmol/ml as deficiency, 50-74.9 nmol/ml as insufficiency, and above 75 nmol/ml asnormal. In addition, endocrine and metabolic variables were evaluated. Among PCOS patients, our findings shows 3[2.4%] normal, 7[5.6%] with insufficiency, 33[26.4%] with deficiency and 82[65.6%] with severe deficiency, whereas in normal participants, 5[4.3%] normal, 4[3.4%] with insufficiency, 28[23.9%] with deficiency and 80[68.4%] with severe deficiency. Comparison of 25[OH]D level between two main groups showed no significant differences [p= 0.65]. Also, the calcium and 25[OH]D levels had no significant differences in pa-tients with overweight [p=0.22] and insulin resistance [p=0.64]. But we also found a relationship between 25[OH]D level and metabolic syndrome [p=0.01]. Furthermore, there was a correlation between 25[OH]D and body mass index [BMI] in control group [p=0.01], while the C-reactive protein [CRP] level was predominantly higher in PCOS group [p<0.001]. Although the difference of 25[OH]D level between PCOS and healthy women is not significant, the high prevalence of 25[OH]D deficiency is a real alarm for public health care system and may influence our results